1 Scopus citations

Abstract

Recent developments in genome editing and delivery systems have opened new possibilities for B cell gene therapy. CRISPR-Cas9 nucleases have been used to introduce transgenes into B cell genomes for subsequent secretion of exogenous therapeutic proteins from plasma cells and to program novel B cell Ag receptor specificities, allowing for the generation of desirable Ab responses that cannot normally be elicited in animal models. Genome modification of B cells or their progenitor, hematopoietic stem cells, could potentially substitute Ab or protein replacement therapies that require multiple injections over the long term. To date, B cell editing using CRISPR-Cas9 has been solely employed in preclinical studies, in which cells are edited ex vivo. In this review, we discuss current B cell engineering efforts and strategies for the eventual safe and economical adoption of modified B cells into the clinic, including in vivo viral delivery of editing reagents to B cells.

Original languageEnglish
Pages (from-to)755-764
Number of pages10
JournalJournal of Immunology
Volume207
Issue number3
DOIs
StatePublished - Aug 1 2021

Fingerprint

Dive into the research topics of 'Vector strategies to actualize B cell-based gene therapies'. Together they form a unique fingerprint.

Cite this